Dr. Reddy's Laboratories Limited (RDY)
- Previous Close
70.92 - Open
73.40 - Bid 74.02 x 800
- Ask 74.07 x 1100
- Day's Range
73.27 - 74.33 - 52 Week Range
53.12 - 77.72 - Volume
216,393 - Avg. Volume
191,262 - Market Cap (intraday)
12.326B - Beta (5Y Monthly) 0.34
- PE Ratio (TTM)
18.88 - EPS (TTM)
3.92 - Earnings Date --
- Forward Dividend & Yield 0.49 (0.69%)
- Ex-Dividend Date Jul 7, 2023
- 1y Target Est
80.16
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
www.drreddys.com25,863
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: RDY
Performance Overview: RDY
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RDY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RDY
Valuation Measures
Market Cap
11.90B
Enterprise Value
11.27B
Trailing P/E
18.88
Forward P/E
19.38
PEG Ratio (5yr expected)
4.68
Price/Sales (ttm)
3.63
Price/Book (mrq)
3.68
Enterprise Value/Revenue
0.04
Enterprise Value/EBITDA
0.13
Financial Highlights
Profitability and Income Statement
Profit Margin
19.24%
Return on Assets (ttm)
12.38%
Return on Equity (ttm)
21.39%
Revenue (ttm)
271.3B
Net Income Avi to Common (ttm)
52.21B
Diluted EPS (ttm)
3.92
Balance Sheet and Cash Flow
Total Cash (mrq)
72.55B
Total Debt/Equity (mrq)
7.41%
Levered Free Cash Flow (ttm)
23.21B
Research Analysis: RDY
Company Insights: RDY
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: RDY
Analyst Report: Dr. Reddy's Laboratories Limited
Dr. Reddy’s is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (22% of its generics sales), Russia (12%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy’s also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy’s has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy’s also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
RatingPrice TargetAnalyst Report: Dr. Reddy's Laboratories Limited
Dr. Reddy’s is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (22% of its generics sales), Russia (12%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy’s also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy’s has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy’s also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
RatingPrice TargetMorningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover
In this edition, cable companies won't tangle up wireless; upside in Downer; initiating coverage of Saia; and Dr. Reddy's, United Airlines Holdings, and Trip.com.
Analyst Report: Dr. Reddy's Laboratories Limited
Dr. Reddy’s is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (22% of its generics sales), Russia (12%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy’s also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy’s has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy’s also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
RatingPrice Target